Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

This study is testing a bortezomib-based chemotherapy combination for patients with acute lymphoblastic leukemia (ALL) — a blood cancer — that has come back or stopped responding to treatment. **You may be eligible if...** - You are between 16 and 60 years old - You have been diagnosed with relapsed or refractory ALL after one or two prior treatments - You may still be eligible even if you have had a prior bone marrow transplant, as long as you are not being treated for graft-versus-host disease **You may NOT be eligible if...** - You have Burkitt leukemia (a specific aggressive subtype) - You have significant liver, kidney, or heart problems - You have an active uncontrolled infection - You have previously been treated with bortezomib - You have a severe psychiatric condition - Your general health status is poor (ECOG above 2) Talk to your doctor to see if this trial is right for you.